APG Asset Management US Inc. Acquires Shares of 3,033 ResMed Inc. (NYSE:RMD)

APG Asset Management US Inc. bought a new stake in shares of ResMed Inc. (NYSE:RMD - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 3,033 shares of the medical equipment provider's stock, valued at approximately $694,000.

A number of other large investors also recently bought and sold shares of the business. Howard Capital Management Inc. increased its holdings in ResMed by 5.3% in the 4th quarter. Howard Capital Management Inc. now owns 900 shares of the medical equipment provider's stock worth $206,000 after acquiring an additional 45 shares in the last quarter. SkyView Investment Advisors LLC lifted its holdings in ResMed by 2.0% in the 3rd quarter. SkyView Investment Advisors LLC now owns 2,610 shares of the medical equipment provider's stock valued at $637,000 after purchasing an additional 51 shares in the last quarter. Wedmont Private Capital boosted its stake in ResMed by 2.6% during the 4th quarter. Wedmont Private Capital now owns 2,032 shares of the medical equipment provider's stock worth $475,000 after purchasing an additional 52 shares during the last quarter. Faithward Advisors LLC grew its holdings in shares of ResMed by 4.3% during the fourth quarter. Faithward Advisors LLC now owns 1,279 shares of the medical equipment provider's stock worth $292,000 after buying an additional 53 shares in the last quarter. Finally, HighPoint Advisor Group LLC raised its position in shares of ResMed by 2.6% in the fourth quarter. HighPoint Advisor Group LLC now owns 2,570 shares of the medical equipment provider's stock valued at $610,000 after buying an additional 64 shares during the last quarter. Institutional investors and hedge funds own 54.98% of the company's stock.

Remove Ads

ResMed Trading Down 1.0 %

ResMed stock traded down $2.16 during midday trading on Tuesday, reaching $212.37. 280,546 shares of the stock traded hands, compared to its average volume of 1,024,237. The firm has a market cap of $31.19 billion, a PE ratio of 25.07, a price-to-earnings-growth ratio of 1.53 and a beta of 0.75. The company has a current ratio of 3.33, a quick ratio of 2.29 and a debt-to-equity ratio of 0.13. The company has a 50-day simple moving average of $225.09 and a two-hundred day simple moving average of $235.22. ResMed Inc. has a 12-month low of $172.19 and a 12-month high of $263.05.

ResMed (NYSE:RMD - Get Free Report) last announced its quarterly earnings data on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share for the quarter, beating analysts' consensus estimates of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%. Research analysts expect that ResMed Inc. will post 9.47 earnings per share for the current fiscal year.

ResMed Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 13th were paid a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 1.00%. The ex-dividend date was Thursday, February 13th. ResMed's payout ratio is currently 25.03%.

Insider Buying and Selling at ResMed

In other news, Director Peter C. Farrell sold 2,000 shares of the company's stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $242.11, for a total transaction of $484,220.00. Following the completion of the transaction, the director now directly owns 77,218 shares of the company's stock, valued at approximately $18,695,249.98. This represents a 2.52 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Michael J. Farrell sold 8,009 shares of the business's stock in a transaction that occurred on Monday, April 7th. The stock was sold at an average price of $209.85, for a total value of $1,680,688.65. Following the sale, the chief executive officer now owns 455,472 shares of the company's stock, valued at approximately $95,580,799.20. The trade was a 1.73 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 49,013 shares of company stock valued at $11,298,816 in the last quarter. Corporate insiders own 0.71% of the company's stock.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. KeyCorp upped their price objective on shares of ResMed from $266.00 to $280.00 and gave the company an "overweight" rating in a research note on Friday, January 31st. JPMorgan Chase & Co. lifted their price objective on ResMed from $270.00 to $286.00 and gave the stock an "overweight" rating in a research report on Friday, January 31st. Needham & Company LLC restated a "hold" rating on shares of ResMed in a report on Friday, January 31st. Piper Sandler lifted their price target on ResMed from $252.00 to $260.00 and gave the stock a "neutral" rating in a report on Friday, January 31st. Finally, The Goldman Sachs Group assumed coverage on shares of ResMed in a report on Thursday, January 16th. They issued a "buy" rating for the company. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $249.73.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.